Observational studyBMJ open2017
Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.
Observational study in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.The patient · 2018Pooled it
- Association of medication adherence with treatment preferences: incentivizing truthful self-reporting.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Trial
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Trial
- Expert assessment of the attributes of high-cost medications: a case study of CAR T-cell therapy in the gulf cooperation council.Frontiers in pharmacology · 2026Article
- Perspective of Disease and Treatment in Patients with Multiple Sclerosis: A Polish Multi-center Study.Neurology and therapy · 2025Article
- Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America.Therapeutic advances in neurological disorders · 2025Article
- Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.Journal of neurology · 2024Article
- Clinical effectiveness of dimethyl fumarate in multiple sclerosis patients from Argentina.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Patient and Physician Perspectives of Treatment Burden in Multiple Sclerosis.Neurology and therapy · 2024Article
- Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management.Therapeutic advances in neurological disorders · 2024Review
- Understanding the value of biobank attributes to researchers using a conjoint experiment.Scientific reports · 2023Article
- Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.Journal of the Medical Library Association : JMLA · 2022Article
- Conjoint Analysis: A Research Method to Study Patients' Preferences and Personalize Care.Journal of personalized medicine · 2022Article
- Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.Patient preference and adherence · 2022Review
- Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence.Patient preference and adherence · 2022Review
- Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists.Frontiers in oncology · 2021Article
- Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.Pharmacy (Basel, Switzerland) · 2020Article
- Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.Frontiers in neurology · 2018Article
- Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Comorbidity and metabolic syndrome in patients with multiple sclerosis from Asturias and Catalonia, Spain.BMC neurology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess patients' preferences for a range of disease-modifying therapy (DMT) attributes in multiple sclerosis (MS).
designA cross-sectional observational study.
settingThe data reported were from 17 MS units throughout Spain.
participantsAdult patients with relapsing-remitting MS. MAIN OUTCOME: A conjoint analysis was applied to assess preferences. A total of 221 patients completed a survey with 10 hypothetical DMT profiles developed using an orthogonal design and rating preferences from 1 (most acceptable) to 10 (least acceptable). Medication attributes included preventing relapse, preventing disease progression, side effect risk, route and frequency of administration.
resultsPatients placed the greatest relative importance on the side effect risk domain (32.9%), followed by route of administration (26.1%), frequency of administration (22.7%), prevention of disease progression (10.0%) and prevention of relapse (8.3%). These results were independent of the Expanded Disability Status Scale score. The importance assigned to side effect risk was highest for patients with a recent diagnosis. Patients who had previously received more than one DMT gave a higher importance to relapse rate reduction than patients receiving their first DMT.
conclusionsPatient DMT preferences were mainly driven by risk minimisation, route of administration and treatment schedule. The risk-benefit spectrum of available DMT for MS is becoming increasingly complicated. Understanding which treatment characteristics are meaningful to patients may help to tailor information for them and facilitate shared decision-making in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.